The relative clinical efficacy of trametinib-dabrafenib and cobimetinib-vemurafenib in advanced melanoma: an indirect comparison

Summary What is known and objective Melanoma causes the majority of skin cancer‐related deaths. The outcome of melanoma depends on its stage at diagnosis. Currently, for patients with advanced melanoma, two MEK inhibitors (trametinib and cobimetinib) have been authorized by the European Medicines Ag...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical pharmacy and therapeutics 2016-06, Vol.41 (3), p.285-289
Hauptverfasser:	Galván-Banqueri, M., Ubago-Pérez, R., Molina-López, T.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - pharmacology Antineoplastic Combined Chemotherapy Protocols - therapeutic use Azetidines - administration & dosage cobimetinib dabrafenib Disease-Free Survival Humans Imidazoles - administration & dosage indirect treatment comparison Indoles - administration & dosage melanoma Melanoma - drug therapy Melanoma - pathology Neoplasm Staging Oximes - administration & dosage Piperidines - administration & dosage Pyridones - administration & dosage Pyrimidinones - administration & dosage Randomized Controlled Trials as Topic Skin Neoplasms - drug therapy Skin Neoplasms - pathology Sulfonamides - administration & dosage Survival Rate trametinib Treatment Outcome vemurafenib
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!